GlassScriptPhysician profile
Daniel Argotte Vilchez
NPI 1316329824
$11,285.20
in general payments reported to CMS, 2019-2025
26 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.28 · 2021: $2,587 · 2022: $4,016 · 2023: $2,792 · 2024: $746 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595 · Travel and Lodging: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.01 |
| Travel and Lodging | $1,070.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,571.60 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Abbott Laboratories | $1,348.99 | 2023-2025 | Diamondback Peripheral, Pressurewire, Mitraclip |
| Edwards Lifesciences Corporation | $1,348.23 | 2022-2024 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $921.72 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $870.43 | 2021-2024 | Avvigo Guidance System, Rotapro, Wolverine Coronary Cutting Balloon |
| Terumo Medical Corporation | $704.74 | 2020-2025 | Metacross Otw, Glidewire, Glidesheath Slender |
| Shockwave Medical, INC | $490.07 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Janssen Pharmaceuticals, INC | $345.01 | 2022-2023 | Xarelto |
| Penumbra, INC. | $339.24 | 2021-2025 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $293.19 | 2023-2025 | Camzyos, Eliquis |
| Zoll Circulation INC | $292.93 | 2022 | |
| Cvrx, INC. | $185.17 | 2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $124.98 | 2022 | |
| Cardiovascular Systems INC. | $120.20 | 2022 | |
| Lilly USA, LLC | $53.85 | 2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.51 | 2022 | |
| Novo Nordisk INC | $32.21 | 2022-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.79 | 2022 | |
| Ethicon INC. | $30.99 | 2025 | Monarch Platform |
| Kestra Medical Technology Services, INC. | $28.60 | 2024 | Assure Wcd |
| Inspire Medical Systems, INC. | $22.42 | 2023 | Inspire |
| Insulet Corporation | $21.46 | 2024 | Omnipod |
| Chiesi USA, INC. | $17.68 | 2024 | Kengreal |
| Shield Therapeutics INC | $17.37 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.67 | 2022 | |
| Pfizer INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vilchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.